Cooperative Agreement U01GH001006

Federal Cooperative Agreement Summary The National Center for Emerging and Zoonotic Infectious Diseases (NCEZID) awarded a $600,000 Cooperative Agreement (CFDA 93.283: Centers for Disease Control and Prevention Investigations and Technical Assistance) to the Liverpool School of Tropical Medicine (LSTM) for monitoring, operations research, and evaluation of malaria control and prevention tools in Kenya. The five-year award, effective September 1, 2025 through August 31, 2030, supports LSTM's...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of North Carolina at Chapel Hill a $1.91 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and validate deep learning surrogate (DLS) models for predicting the spread of artemisinin partial resistance in malaria parasites across Africa. Awarded September 25, 2025, with a completion date of August 31, 2030, this research addresses a critical public...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $451,000 to the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 15, 2025, with completion scheduled for July 31, 2027. This Project Grant supports the development and application of high-resolution phage immunoprecipitation sequencing (PhIP-Seq) arrays designed to comprehensively evaluate antibody responses to...

Federal Grant Award Summary Emory University received a $241,888 Project Grant from the Fogarty International Center (FIC) under the International Research and Research Training program (CFDA 93.989), awarded September 15, 2025, with completion targeted for March 31, 2030. The grant supports "Building an India-Africa Network to Support Research and Control of Urban Malaria Transmission," a capacity-building initiative addressing the emergence of Anopheles stephensi, an urban malaria...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $1,351,924 to The Regents of the University of California, San Francisco (UCSF) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize interactions between human and vector behaviors in order to enhance malaria control interventions in Uganda. The project, which commenced August 11, 2025, and extends through July 31, 2030, addresses the stalled progress in...

Federal Project Grant Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Johns Hopkins University a Project Grant of $426,938 effective August 1, 2025 through July 31, 2027 under the Allergy and Infectious Diseases Research program (CFDA 93.855). The research focuses on evaluating combined inhibition strategies against Plasmodium falciparum merozoite invasion into erythrocytes, a critical target for antimalarial drug development. The project will assess the...

This $1,480,500 federal Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310) will fund research by The Trustees of Columbia University in the City of New York to identify and characterize the roles of non-coding RNAs in regulating drug-induced quiescence in Plasmodium falciparum, the parasite that causes malaria. The project aims to uncover novel epigenetic and epitranscriptomic mechanisms that enable...

Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant of $807,330 on August 12, 2025, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Massachusetts General Hospital to develop potent antibody therapeutics against malaria parasites. The research, scheduled for completion by July 31, 2030, focuses on identifying and characterizing highly effective human monoclonal antibodies targeting the circumsporozoite...

This $388,004 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports investigator-initiated research conducted by The Washington University in St. Louis to elucidate heme homeostasis mechanisms in the malaria parasite Plasmodium falciparum. The research addresses a critical global health challenge, as malaria remains the deadliest vector-borne disease, responsible for 249...

Federal Project Grant Award Summary Griffith University received a $549,032 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 10, 2025, with completion targeted for August 31, 2028. The award supports the design, manufacture, and evaluation of biopolymer particle-based multistage malaria vaccine candidates intended to prevent infection caused by Plasmodium falciparum....